Marino Garcia
CIK: 0001669866
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Sep 11, 2026AGMB
AgomAb Therapeutics NV
Award(A)DirectStock Option (Right to Buy)
57.5K shares- - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct2.4K shares at avg. $109.10$259K - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct2.5K shares at avg. $110.02$279K - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct10.4K shares at avg. $107.49$1.1M - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct40K shares at avg. $8.44$338K - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct23.9K shares at avg. $108.05$2.6M - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct800 shares at avg. $110.76$89K - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct104.1K shares at avg. $107.96$11.2M - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct21.9K shares at avg. $108.72$2.4M - Aug 7, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct126K shares at avg. $8.44$1.1M - Mar 16, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct5.6K shares at avg. $17.88$100K - Mar 16, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct59.7K shares at avg. $6.70$400K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct43.5K shares at avg. $80.69$3.5M - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct122.9K shares at avg. $6.70$824K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct65.5K shares at avg. $81.74$5.4M - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct12.8K shares at avg. $82.60$1.1M - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct200 shares at avg. $83.38$17K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct900 shares at avg. $85.53$77K - Feb 3, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
355K shares- - Sep 30, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
120K shares- - Feb 3, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
340K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 11, 2026 |  AGMB AgomAb Therapeutics NV | Award(A) Stock Option (Right to Buy) | 57,482 | - | - | Direct |
| Aug 7, 2026 |  DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 2,373 | $109.10 | $258,894 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 2,536 | $110.02 | $279,011 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 10,384 | $107.49 | $1,116,176 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 40,000 | $8.44 | $337,600 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 23,907 | $108.05 | $2,583,151 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 800 | $110.76 | $88,608 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 104,091 | $107.96 | $11,237,664 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 21,909 | $108.72 | $2,381,946 | Direct |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 126,000 | $8.44 | $1,063,440 | Direct |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 5,592 | $17.88 | $99,985 | Direct |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 59,700 | $6.70 | $399,990 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 43,505 | $80.69 | $3,510,418 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 122,918 | $6.70 | $823,551 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 65,517 | $81.74 | $5,355,360 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 12,796 | $82.60 | $1,056,950 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 200 | $83.38 | $16,676 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 900 | $85.53 | $76,977 | Direct |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 355,000 | - | - | Direct |
| Sep 30, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 120,000 | - | - | Direct |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 340,000 | - | - | Direct |
1-21 of 21 transactions
About Garcia Marino
Garcia Marino (SEC CIK 0001669866) files insider reports with the SEC as Director of AgomAb Therapeutics NV (AGMB) and CEO AND PRESIDENT of Dianthus Therapeutics, Inc. /DE/ (DNTH).
Signal8 holds 8 ownership filings by Garcia Marino (1 Form 3, 7 Form 4), filed between Feb 4, 2025 and Sep 15, 2026. Those filings report 21 transactions, from Feb 3, 2025 to Sep 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Garcia Marino's filings is in ANTWERPEN.
Recent filings by Garcia Marino
- Sep 11, 2026: Grant or award of AGMB derivative securities (Form 4, code A).
- Aug 7, 2026: Open-market sales of DNTH shares (3 lines, Form 4, code S).
- Aug 7, 2026: Option exercise of DNTH shares (Form 4, code M).
- Aug 7, 2026: Open-market sales of DNTH shares (4 lines, Form 4, code S).
- Aug 7, 2026: Option exercise of DNTH shares (Form 4, code M).
Other insiders filing for AgomAb Therapeutics NV (AGMB)
- Epstein David R, Director
- Kemula Pierre Thadee Victor, Chief Financial Officer
- Knotnerus Tim Jasper, Chief Executive Officer
- Patel Naimish, Director
- Bond Colin Michael, Director
- Hammer Ohad, Director